Fujifilm Medical Systems U.S.A., Inc., Lexington, Mass., and Volpara Solutions (now Volpara Health), Wellington, New Zealand, a purpose-driven software company on a mission to prevent advanced-stage breast cancer, announced an expanded partnership to provide mammography facilities and clinicians with breast imaging solutions designed to improve image quality, streamline workflow, and accurately assess a patient’s breast density.
Building on a successful 6-year partnership, Fujifilm’s customers using Aspire Cristalle with Digital Breast Tomosynthesis (DBT) now have access to the latest innovations from Volpara’s Breast Health Platform. VolparaLive! helps reduce patient recalls due to poor image quality by giving mammographers instant feedback on positioning and compression—which the FDA attributes as the cause of most image deficiencies—for adjustment before the patient leaves the room. Volpara Enterprise provides a comprehensive analysis of quality on every mammogram and tomosynthesis image taken at the facility to identify opportunities for improvement.
“Consistent mammography quality and accuracy are critical to ensuring that we are able to provide women the best possible breast health care. We are excited to work with Fujifilm and Volpara to implement a system-wide quality program across our entire network, including the University of Utah’s Huntsman Cancer Institute and our Community Breast Care Centers,” says Laurie Fajardo, MD, Professor of Radiology at the University of Utah, School of Medicine and the Department of Radiology and Imaging Sciences. “We expect the objective data provided by Volpara will be a tremendous tool in both our quality improvement and productivity efforts, and will significantly streamline our accreditation processes.”
Dense breast tissue is associated with an increased risk of developing breast cancer.1 Volpara’s Enterprise includes a module that uses proprietary x-ray physics, AI, and machine learning to generate an accurate volumetric measure of breast composition. It provides a repeatable, consistent, and objective means of scoring breast density.
“Early detection is critical to breast cancer survival. It’s essential that clinicians and patients have as many resources available to them to quickly and accurately find any possible signs of disease,” says Christine Murray, Women’s Health Product Manager, Fujifilm Medical Systems U.S.A., Inc. “Fujifilm is thrilled to expand our relationship with Volpara Solutions to offer our customers the clinical decision-support tools they need to improve mammography quality and enhance patient care.”
“Providing an accurate and consistent assessment of breast density is vital to identifying women at high risk of developing breast cancer and determining their screening path,” says Katherine Singson, CEO, Volpara Solutions. “Volpara’s AI-based breast health platform, coupled with a leading modality solution like the Fujifilm Aspire Cristalle, offers a powerful combination to identify this destructive disease in its early stages.”
For more information, visit Fujifilm.
1 Boyd et al. N Engl J Med 2007; 356, 227